Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp grew its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 6.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,400 shares of the biopharmaceutical company’s stock after purchasing an additional 2,600 shares during the quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s holdings in Regeneron Pharmaceuticals were worth $14,283,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ostrum Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at $108,000. Icon Wealth Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at $112,000. Signaturefd LLC grew its holdings in shares of Regeneron Pharmaceuticals by 123.8% during the second quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 198 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at $159,000. Finally, Summit Trail Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 22,971.8% during the first quarter. Summit Trail Advisors LLC now owns 166,348 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 165,627 shares during the last quarter. 66.90% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have recently weighed in on the stock. Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $396.00 to $409.00 and gave the company an “equal weight” rating in a report on Friday, August 3rd. Argus boosted their price objective on shares of Regeneron Pharmaceuticals from $383.00 to $415.00 and gave the company a “buy” rating in a report on Monday, July 16th. UBS Group raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Wednesday, June 27th. BidaskClub lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 11th. Finally, SunTrust Banks set a $344.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Monday, July 2nd. Two research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $411.48.
In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 104,552 shares of the company’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $406.68, for a total value of $42,519,207.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman P Roy Vagelos sold 74,710 shares of the company’s stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $327.87, for a total transaction of $24,495,167.70. Following the completion of the transaction, the chairman now owns 553,121 shares of the company’s stock, valued at approximately $181,351,782.27. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 259,432 shares of company stock worth $96,485,427. 12.42% of the stock is owned by corporate insiders.
NASDAQ:REGN opened at $397.71 on Friday. Regeneron Pharmaceuticals Inc has a one year low of $281.89 and a one year high of $477.00. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.92 and a current ratio of 3.62. The firm has a market capitalization of $42.55 billion, a price-to-earnings ratio of 29.66, a price-to-earnings-growth ratio of 1.32 and a beta of 1.23.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 EPS for the quarter, beating the consensus estimate of $4.60 by $0.85. Regeneron Pharmaceuticals had a net margin of 25.65% and a return on equity of 29.30%. The company had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same period in the prior year, the company earned $4.17 earnings per share. The firm’s revenue was up 9.4% on a year-over-year basis. sell-side analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.4 earnings per share for the current year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: Discover Your Risk Tolerance
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.